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Prevalence of Metabolic Syndrome in Patients
with Psoriasis: A Population-Based Study in the
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Sine´ad M. Langan1,2, Nicole M. Seminara2, Daniel B. Shin2, Andrea B. Troxel3,4, Stephen E. Kimmel5,
Nehal N. Mehta3,5, David J. Margolis2,3 and Joel M. Gelfand2,3,4
Increasing epidemiological evidence suggests independent associations between psoriasis and cardiovascular
and metabolic disease. Our objective was to test the hypothesis that directly assessed psoriasis severity relates
to the prevalence of metabolic syndrome and its components. A population-based, cross-sectional study was
undertaken using computerized medical records from the Health Improvement Network Study population
including individuals in the age group of 45–65 years with psoriasis and practice-matched controls. The
diagnosis and extent of psoriasis were determined using provider-based questionnaires. Metabolic syndrome
was defined using the National Cholesterol Education Program Adult Treatment Panel III criteria. A total of
44,715 individuals were included: 4,065 with psoriasis and 40,650 controls. In all, 2,044 participants had mild
psoriasis (p2% body surface area (BSA)), 1,377 had moderate psoriasis (3–10% BSA), and 475 had severe psoriasis
(410% BSA). Psoriasis was associated with metabolic syndrome, adjusted odds ratio (adj. OR 1.41, 95%
confidence interval (CI) 1.31–1.51), varying in a ‘‘dose–response’’ manner, from mild (adj. OR 1.22, 95% CI
1.11–1.35) to severe psoriasis (adj. OR 1.98, 95% CI 1.62–2.43). Psoriasis is associated with metabolic syndrome
and the association increases with increasing disease severity. Furthermore, associations with obesity,
hypertriglyceridemia, and hyperglycemia increase with increasing disease severity independently of other
metabolic syndrome components. These findings suggest that screening for metabolic disease should be
considered for psoriasis, especially when it is severe.
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INTRODUCTION
The metabolic syndrome is a clustering of cardiovascular
risk factors, specifically obesity, hypertension, dyslipidemia,
and insulin resistance (Eckel et al., 2005), which has been
associated with an increased risk of cardiovascular disease
(CVD) beyond traditional risk factors (Mente et al., 2010).
The prevalence of metabolic syndrome is increasing in the
United States (US; Ford et al., 2002) and partly in Europe,
paralleling the rising prevalence of obesity worldwide
(Mokdad et al., 2003; Mente et al., 2010). Systemic inflam-
mation is associated with metabolic syndrome, with T helper
type 1 proinflammatory cytokines such as tumor necrosis
factor-a and nonspecific measures of inflammation such as
C-reactive protein levels being elevated in patients with the
syndrome compared with those without (Lakka et al., 2002).
However, there is a limited understanding of the relationship
between chronic inflammatory diseases and the prevalence
of metabolic syndrome.
Psoriasis is the most common T helper type 1 inflamma-
tory disease, affecting more than 125 million people world-
wide (National Psoriasis Foundation). The severity of psoriasis
in the general population is variable, with most patients
having mild disease (Kurd and Gelfand, 2009), defined as
involving p2% of the body surface area (BSA). Epidemio-
logical evidence suggests that psoriasis is associated with
an increased frequency of cardiovascular risk factors and
adverse cardiovascular outcomes, including myocardial
infarction (Gelfand et al., 2006), stroke (Gelfand et al.,
2009), and cardiovascular death (Mehta et al., 2010a).
Psoriasis, especially if severe, may be a risk factor for athero-
sclerotic CVD, beyond traditional risk factors (Gelfand et al.,
2006, 2009; Mehta et al., 2010a). Moreover, patients with
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severe psoriasis die at an age approximately 5 years younger
than patients without psoriasis, with CVD being the most
common cause of the excess mortality in these patients
(Abuabara et al., 2010). Mechanistic studies of the meta-
bolic syndrome (Shah et al., 2009) and insulin resistance
(Mehta et al., 2010b) suggest that chronic T helper type 1
inflammation that characterizes psoriasis, metabolic syn-
drome, diabetes, and CVD may partly explain the association
between these phenotypically distinct diseases.
A number of small, epidemiological studies have reported
associations between psoriasis and the metabolic syndrome
(Azfar and Gelfand, 2008; Gisondi and Girolomoni, 2009;
Al-Mutairi et al., 2010; Mebazaa et al., 2011); however,
population-based data in which the severity of psoriasis
is objectively determined and individual components of
the metabolic syndrome are directly measured are lacking
(Augustin et al., 2010). Therefore, our objective was to
examine whether there is an association between psoriasis
and the metabolic syndrome in a broadly representative
population of patients. We also investigate whether the
degree of association varies with the extent of skin involve-
ment with psoriasis.
RESULTS
Table 1 describes the demographics of the study population.
At the end of the survey collection period, 4,634 of 4,900
provider-based surveys were completed, giving a response
rate of 95%. Our cohort included 4,065 people with
confirmed psoriasis and 40,650 matched controls. The mean
age of psoriasis patients was 1.2 years higher than that of
controls (Po0.001), and 51% of psoriasis patients were male
compared with 48% of controls (Po0.001). A total of 2,044
(53%) participants had mild psoriasis (p2% BSA), 1,377
(35%) had moderate psoriasis (3–10% BSA), and 475 (12%)
had severe psoriasis (410% BSA). Information on body
mass index (BMI), blood pressure, high-density lipoprotein,
glucose, and triglyceride levels was available for 41,249
(92%), 44,019 (98%), 25,234 (56%), 28,743 (64%), and
25,067 (56%) of the patients, respectively (Table 2a). These
measurements were available in similar numbers of patients
with and without psoriasis.
Metabolic syndrome was identified in 34% of participants
with psoriasis compared with 26% of controls (odds ratio
(OR) 1.50, 95% confidence interval (CI) 1.40–1.61). This
association persisted after adjusting for age, gender, and
follow-up (adjusted (adj.) OR 1.41, 95% CI 1.31–1.51).
Adjusting for smoking and social class did not change the
study findings, and these were not retained in the final model.
Psoriasis severity affected the degree of association, with
the metabolic syndrome seen in 32% of the patients
with mild disease (adj. OR 1.22, 95% CI 1.11–1.35), 36%
with moderate disease (adj. OR 1.56, 95% CI 1.38–1.76), and
40% with severe psoriasis (adj. OR 1.98, 95% CI 1.62–2.43).
Modest but statistically significant interactions were detected
between psoriasis and age, and between psoriasis and sex,
whereby the OR of metabolic syndrome and psoriasis
was slightly higher in the younger age groups and in women
(data not shown).
On studying the components of the metabolic syndrome,
the following factors were found to be more common in
psoriasis patients than in controls: obesity in 38% vs. 31%
(OR 1.38, 95% CI 1.29–1.48), raised triglyceride levels in
36% vs. 28% (OR 1.49, 95% CI 1.39–1.60), diagnosed
hypertension in 31% vs. 28% (OR 1.20, 95% CI 1.11–12.9),
and raised glucose levels in 22% vs. 16% (OR 1.44, 95% CI
1.33–1.56; Table 2a).
On studying the fully adjusted model to understand
which components of the metabolic syndrome were asso-
ciated with psoriasis after adjusting for other elements of
the metabolic syndrome and age, gender, and duration of
follow-up, the strongest association of a component of the
metabolic syndrome and psoriasis was found with obesity
(adj. OR 1.25, 95% CI 1.16–1.34). The association with
Table 1. Demographic details of the cohort
Characteristic
No
psoriasis, n (%)
Psoriasis,
n (%)
Overall 40,650 (90.9) 4,065 (9.1)
By psoriasis extent
p2% N/A 2,044 (52.5)
3–10% N/A 1,377 (35.3)
410% N/A 475 (12.2)
Gender
Men 19,304 (47.5) 2,081 (51.2)
Women 21,346 (52.5) 1,984 (48.8)
Age group (years)
o50 13,348 (32.8) 1,082 (26.6)
50–54 10,040 (24.7) 1,000 (24.6)
55–59 9,271 (22.8) 945 (23.3)
460 7,991 (19.7) 1,038 (25.5)
Median (interquartile range) of
maximum individual measurements
Body mass index (kgm2) 27.1 (23.7–31.2) 28.4 (24.9–32.9)
Systolic blood pressure (mmHg) 144 (130–162) 149 (135–168)
Diastolic blood pressure (mmHg) 90 (80–100) 90 (82–100)
Triglyceride level (mmol/l) 1.7 (1.1–2.5) 1.9 (1.2–2.8)
Cholesterol level (mmol/l) 5.8 (5.1–6.7) 6.0 (5.2–6.8)
High-density lipoprotein (mmol/l) 1.5 (1.2–1.8) 1.4 (1.2–1.7)
Low-density lipoprotein (mmol/l) 3.6 (2.9–4.3) 3.7 (3.0–4.3)
Glucose (mmol l1) 5.4 (4.9–6.4) 5.6 (4.9–6.6)
C reactive protein (mg l1) 5 (3–10) 7 (4–13)
Metabolic syndrome, n (%) 10,515 (25.9) 1,389 (34.2)
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obesity demonstrated a dose–response relationship, with a
14% increase in obesity in those with mild psoriasis (adj. OR
1.14, 95% CI 1.03–1.27), 34% increase in obesity in those
with moderate psoriasis (adj. OR 1.34, 95% CI 1.18–1.53),
and a 66% increased odds of being obese in those with
severe psoriasis (adj. OR 1.66, 95% CI 1.33–2.07; Tables 2b
and 3). Hypertriglyceridemia and hyperglycemia showed
similar dose–response relationships with severity of psoriasis.
There was a 20% increased odds of having raised triglyceride
levels in individuals with psoriasis overall, independent of
obesity (adj. OR 1.20, 95% CI 1.10–1.31). This association
also demonstrated an increased odds of having raised
triglyceride levels, from 10% in those with mild psoriasis
(adj. OR 1.10, 95% CI 0.98–1.25) to 46% in those with severe
psoriasis (adj. OR 1.46, 95% CI 1.13–1.88). Raised glucose
level was also associated with psoriasis independent of
Table 2a. Factors associated with the metabolic syndrome
Factors associated with metabolic syndrome No psoriasis, n (%) Psoriasis, n (%) OR (95% CI)
Body mass index o25 kgm2 1 10,744 (28.7) 827 (21.9) 1.0
Body mass index 25–o30 kgm2 1 14,143 (37.7) 1,401 (37.1) 1.30 (1.19–1.42)
Body mass index 30–o35 kgm2 1 7,678 (20.5) 887 (23.5) 1.52 (1.37–1.68)
Body mass index 435 kgm2 1 4,907 (13.1) 662 (17.5) 1.78 (1.59–1.98)
Triglyceride levels X1.7mmol l1 2 11,181 (27.5) 1,453 (35.7) 1.49 (1.39–1.60)
Low HDL (o1.04mmol l1 (men) and o1.29mmol l1 (women))3 8,180 (20.1) 1,007 (24.7) 1.32 (1.22–1.43)
Raised BP (systolicX130mmHg or diastolicX85mmHg)4 24,187 (59.5) 3,571 (87.9) 1.36 (1.24–1.50)
Hypertension diagnosis 11,204 (27.6) 1,265 (31.1) 1.20 (1.11–12.9)
Type 2 diabetes mellitus 3,445 (8.5) 454 (11.2) 1.36 (1.23–1.51)
High-glucose measurement (46.1mmol l1)5 6,644 (16.3) 884 (21.8) 1.44 (1.33–1.56)
Abbreviations: BP, blood pressure; CI, confidence interval; HDL, high-density lipoprotein; OR, odds ratio.
1BMI measured in 41,249: 3,777 (93%) with psoriasis, 37,472 (92%) controls.
2Triglycerides measured in 25,067: 2,545 (63%) with psoriasis, 22,522 (55%) controls.
3HDL measured in 25,234: 2,538 (62%) with psoriasis, 22,696 (56%) controls.
4BP measured in 44,019: 4,023 (99%) with psoriasis, 39,996 (98%) controls.
5Glucose measured in 28,743: 2,599 (64%) with psoriasis, 26,144 (64%) controls.
Table 2b. Factors including psoriasis extent associated with the metabolic syndrome
Factors associated with the
metabolic syndrome
No psoriasis
(n, %)
Mild psoriasis (n, %),
OR (95% CI)
Moderate psoriasis (n, %),
OR (95% CI)
Severe psoriasis (n, %),
OR (95% CI)
Body mass index o25 kgm2 1 10,744 (28.7) 472 (24.7), 1.0 247 (19.4), 1.0 72 (16.6), 1.0
Body mass index 25–o30 kgm2 1 14,143 (37.7) 715 (35.0), 1.15 (1.02–1.30) 483 (35.1), 1.49 (1.27–1.74) 140 (32.2), 1.48 (1.11–1.96)
Body mass index 30–o35 kgm2 1 7,678 (20.5) 415 (21.7), 1.23 (1.07–1.41) 316 (24.8), 1.79 (1.51–2.12) 126 (29.0), 2.45(1.83–3.28)
Body mass index 435 kgm2 1 4,907 (13.1) 310 (16.2), 1.44 (1.24–1.67) 228 (17.9), 2.02 (1.68–2.43) 97 (22.3), 2.94 (2.17–4.01)
TriglyceridesX1.7mmol l1 2 11,181 (27.5) 686 (33.6), 1.33 (1.21–1.46) 511 (37.1), 1.56 (1.39–1.74) 202 (42.5), 1.95 (1.62–2.34)
Low HDL (o1.04mmol l1 (men) and
o1.29mmol l1 (women))3
8,180 (20.1) 480 (23.5), 1.22 (1.10–1.35) 348 (25.3), 1.34 (1.19–1.52) 139 (29.3), 1.64 (1.35–2.00)
Raised BP (SystolicX130mmHg or
diastolicX85mmHg)4
24,187 (59.5) 1,306 (63.9), 1.20 (1.10–1.32) 907 (65.9), 1.31 (1.17–1.47) 329 (69.3), 1.53 (1.26–1.87)
Hypertension diagnosis 11,204 (27.6) 627 (30.7), 1.16 (1.06–1.28) 433 (31.5), 1.21 (1.07–1.35) 151 (31.8), 1.21 (0.98–1.49)
Type 2 diabetes mellitus 3,445 (8.5) 220 (10.8), 1.28 (1.11–1.48) 150 (10.9), 1.30 (1.10–1.56) 58 (12.2), 1.50 (1.14–1.98)
High-glucose measurement
(46.1mmol lmmHg)5
6,644 (16.3) 429 (21.0), 1.36 (1.22–1.52) 291 (21.1), 1.37 (1.20–1.57) 129 (27.2), 1.91 (1.56–2.34)
Abbreviations: BP, blood pressure; CI, confidence interval; HDL, high-density lipoprotein; OR, odds ratio.
1BMI measured in 41,249: 3,777 (93%) with psoriasis, 37,472 (92%) controls.
2Triglycerides measured in 25,067: 2,545 (63%) with psoriasis, 22,522 (55%) controls.
3HDL measured in 25,234: 2,538 (62%) with psoriasis, 22,696 (56%) controls.
4BP measured in 44,019: 4,023 (99%) with psoriasis, 39,996 (98%) controls.
5Glucose measured in 28,743: 2,599 (64%) with psoriasis, 26,144 (64%) controls.
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obesity, with a 16% increased odds of raised glucose overall
(adj. OR 1.16, 95% CI 1.06–1.27), with the association being
strongest in the group with the most severe disease (Table 3).
Sensitivity analysis using the revised Adult Treatment
Panel (ATP) III, International Diabetes Federation criteria or
by limiting lab values to the first or most recent observation,
and excluding individuals on psoriasis treatments that are
known to have an impact on components of the metabolic
syndrome, e.g., ciclosporin or acitretin, did not significantly
change the study conclusions (data not shown).
DISCUSSION
Psoriasis is associated with the metabolic syndrome in a
‘‘dose–response’’manner, with a 22% increase in the odds
of developing the metabolic syndrome in those with mild
psoriasis, 56% increase in those with moderate disease, and
a 98% increase in those with severe psoriasis. In a fully
adjusted model looking at associations between factors
comprising the metabolic syndrome and psoriasis after
adjusting for other components, independent associations
were seen between psoriasis and obesity (25% increased
odds), raised triglyceride levels (20% increased odds), and
raised serum glucose levels (16% increased odds in a
‘‘dose–response’’ manner from mild to severe psoriasis).
The strengths of this investigation are that it is a large
population-based study with a population broadly represen-
tative of the UK population in the age group of 45–65 years,
which minimizes selection bias and increases the external
validity (i.e., generalizability) of the findings. The ‘‘dose–
response’’ association detected provides compelling evi-
dence for an association between psoriasis and the metabolic
syndrome. Study findings were based on laboratory values
and objectively measured disease extent, which allowed
observation of findings that are to our knowledge previously
unreported. Observational study designs are associated with
a number of limitations. These include the cross-sectional
nature of this study, which does not allow us to determine
which developed first— psoriasis or the metabolic syndrome.
Second, we cannot be certain that psoriasis caused the meta-
bolic syndrome; factors including diet, physical inactivity,
alcohol, or genetic predisposition, which have not been
evaluated in this study, may be functioning as confounding or
effect-modifying factors in this relationship (Davidovici et al.,
2010), leading to the possibility of residual confounding.
In terms of information bias, two aspects of this study make
this an unlikely explanation for the findings: (1) laboratory
and clinical values were recorded at similar rates in psoriasis
patients and controls as part of routine medical care by
general practitioners (GPs) unaware of the hypothesis under
study; (2) the persistence of the study findings in the
sensitivity analysis restricted to the first laboratory or clinical
value per person. Disease severity was determined by asking
the GPs to rate the extent of skin involvement with psoriasis
into simple discrete categories.
Although previous studies have suggested that UK GPs are
reasonably accurate in terms of diagnosing psoriasis (Basarab
et al., 1996), direct data on the accuracy of GP assessment of
the extent of skin involvement with psoriasis are not, to our
knowledge, available. We have previously demonstrated the
‘‘construct validity’’ of this approach in that patients rated by
GPs as having higher BSA categories are more likely to
require frequent visits for psoriasis and require systemic
therapy specific for psoriasis or phototherapy (Seminara et al.,
2011). Moreover, we used the same categories used in
the epidemiological studies conducted by NHANES and NPF
in which patients are asked to rate their degree of skin
involvement with psoriasis, suggesting that this approach
is acceptable (i.e., ‘‘face’’ validity; Dommasch et al., 2010;
Krueger et al., 2001; Seminara et al., 2011). Moreover, these
data represent ‘‘real-world’’ data, where the extent of
psoriasis has been assessed by hundreds of GPs around the
UK and resulted in discrimination of the prevalence of
metabolic disorders based on these clinical assessments,
demonstrating the usefulness of this approach. Nevertheless,
our findings are subject to a form of error (i.e., misclassifica-
tion of the extent of skin involvement) that would be expected
to be non-differential and thus bias toward the null. GPs were
asked to assess the BSA of involvement that the patient
typically demonstrates; this measure may not be stable over
time, although a previous large cohort study demonstrated
Table 3. Association between psoriasis severity and components of the metabolic syndrome independent of other
components
Psoriasis extent
High
blood pressure,
OR (95% CI)
Raised
triglyceride levels,
OR (95% CI)
Low HDL,
OR (95% CI)
Hyperglycemia,
OR (95% CI)
Obesity
(BMI 430 kgm2),
OR (95% CI)
No psoriasis, n=40,650 1.0 1.0 1.0 1.0 1.0
Psoriasis overall, n=4,065 1.07 (0.96–1.19) 1.20 (1.10–1.31) 0.98 (0.89–1.08) 1.16 (1.06–1.27) 1.25 (1.16–1.34)
By extent
Mild psoriasis (p2%), n=2,044 1.03 (0.89–1.20) 1.10 (0.98–1.25) 0.99 (0.87–1.13) 1.11 (0.97–1.26) 1.14 (1.03–1.27)
Moderate psoriasis (3–10%), n=1,377 1.02 (0.85–1.24) 1.31 (1.13–1.51) 0.94 (0.80–1.11) 1.16 (0.99–1.35) 1.34 (1.18–1.53)
Severe psoriasis (410%), n=475 1.32 (0.91–1.92) 1.46 (1.13–1.88) 1.05 (0.80–1.39) 1.31 (1.00–1.71) 1.66 (1.33–2.07)
Abbreviations: BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; OR, odds ratio.
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that despite various therapeutic interventions the severity of
psoriasis for individuals did not generally change over time
(Nijsten et al., 2007).
This study significantly advances the existing literature on
psoriasis and the metabolic syndrome, as this is the first
population-based study to use objective measures of psoriasis
severity, direct measurement of the components of metabolic
syndrome, and standard criteria for diagnosis of metabolic
syndrome. Of special interest is the clear ‘‘dose–response’’
relationship between psoriasis severity and the metabolic
syndrome. No previous study has, to our knowledge, shown a
directional increase in the association with raised triglyceride
levels and increasing psoriasis severity independent of the
effects of obesity. The consistency with other study findings
(Gisondi and Girolomoni, 2009; Al-Mutairi et al., 2010;
Augustin et al., 2010; Love et al., 2011; Mebazaa et al.,
2011), presence of a ‘‘dose–response’’ relationship, strong
associations, and biological plausibility support some cau-
sality, but further mechanistic and longitudinal studies are
required (Rothman and Greenland, 2005).
A possible biological mechanism that may account for this
association is that the proinflammatory state associated with
psoriasis functions as a central driving force for development
of the metabolic syndrome. In psoriasis patients, Th1
inflammatory cytokines, e.g., tumor necrosis factor-a, IL-1,
and IL-6, are increased in skin and blood (Azfar and Gelfand,
2008). These inflammatory mediators may have a range of
effects on insulin signaling, lipid metabolism, and adipogen-
esis. In addition, inflammation-induced insulin resistance
may lead to the development of a systemic insulin-resistant
state (Mehta et al., 2010b). Further mechanistic studies will
be needed to test this hypothesis.
Study findings demonstrate a strong association between
psoriasis and the metabolic syndrome, with increasing
psoriasis severity being associated with increasing odds of
metabolic syndrome. Increased odds of raised triglyceride
levels and serum glucose were seen in individuals with
psoriasis independent of the effects of obesity. The results of
this study firmly establish that the metabolic syndrome is an
important comorbidity with psoriasis, and that vigilance and
enhanced screening may be important in psoriasis patients,
particularly those with severe disease. Examining the compo-
nents of metabolic syndrome associated with psoriasis,
weight reduction is clearly a key step to prevent CVD;
however, our findings also show the importance of screening
for the other components of metabolic syndrome, particularly
hypertriglyceridemia and raised glucose levels, as these tests
are more likely to be abnormal in patients with psoriasis
independent of traditional risk factors (such as obesity). Small
increases in the individual components of metabolic syn-
drome have led to an 8% absolute increase in the prevalence
of metabolic syndrome overall and a 14% increase in those
with severe psoriasis. Further prospective studies are required
to determine the directionality of the association between
psoriasis and metabolic syndrome and to study other
unexplored confounders, including diet, physical activity,
alcohol, and genetic factors, which may be important
residual confounders in this relationship.
MATERIALS AND METHODS
Study design
We conducted a cross-sectional study using The Health Improve-
ment Network (THIN).
Study population
THIN is a computerized longitudinal general-practice database
with demographic data similar to the general United Kingdom
(UK) population. THIN has anonymized medical record data on 3.4
million ‘‘active’’ patients followed up for a cumulative 50 million
person years, and is broadly representative of the UK population.
The THIN database contains demographic details, diagnoses,
laboratory results, and prescriptions recorded by GPs, the gate-
keepers for medical care in the UK. The version of THIN we used
contained data from 413 general practices that use the ‘‘In Practice
Vision’’ software. A number of studies have confirmed that THIN
data are highly accurate, thus making it ideal for use in epidemio-
logical research (Lewis et al., 2007; Seminara et al., 2011). The
cohort was identified from individuals in the age group of 45–64
years with at least one psoriasis Read code (using a previously
validated coding algorithm (Seminara et al., 2011)) in the 2 years
before the survey. Patients were required to be registered with a
general practice contributing actively to Additional Information
Services (AIS). AIS practices have an agreement to respond to
questionnaires; 55% (n¼ 228) of THIN practices were AIS active at
the time of sampling. A total of 4,900 eligible patients with psoriasis
diagnostic codes were randomly sampled, and questionnaires were
sent to their GPs through AIS to verify the presence of psoriasis and
the extent of disease. Up to 10 controls in the age group of 45–64
years were randomly matched to each psoriasis patient based on
practice; similar to cases, controls needed to be alive and actively
registered with at least one GP visit within 2 years at the time of
sampling.
Outcomes
Patients were defined as having psoriasis if their diagnosis was
confirmed by a questionnaire completed by their GP. The
questionnaire also determined the severity of psoriasis, namely mild
psoriasis (o2% BSA), moderate psoriasis (3–10% BSA), and severe
psoriasis (410% BSA). This approach has been previously well
accepted (Feldman, 2004). Cardiovascular risk factors, specifically
BMI calculated using standard formulation (overweight was
defined as BMIX25 kgm2 and o30 kgm2, obese was defined as
X30 kg/m2), hypertension, hyperlipidemia, smoking, and diabetes
mellitus, were identified by the presence of diagnostic Read codes
and additional recording and laboratory values in the Additional
Health Details portion of the database.
Subjects were defined as having metabolic syndrome using the
National Cholesterol Education Program (NCEP) ATP III diagnostic
criteria (Expert Panel on Detection, 2001). Using NCEP criteria,
a person with metabolic syndrome fulfills three or more of the
following criteria: central obesity (determined by a BMIX30 kgm2
in THIN), hypertriglyceridemia X1.7mmol l1, low high-density
lipoprotein cholesterol (in men o1.03mmol l1 and in women
o1.29mmol l1), high blood pressure (X130/85mmHg) and high
fasting glucose level (X6.1mmol l1). Time-varying variables were
dealt with by selecting the maximum laboratory value or clinical
measurement and using the most recent value for BMI. Conditions
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were measured from the patients’ start date (defined as the latest of
the Vision software or computerization in the practice and
registration dates of the patient), whereas the end of the study was
defined as the earliest date of transfer out, death, or end of the study
period in February 2009.
Study size
We calculated that a sample size of 4,900 would yield 4,190
patients, which would be sufficient to detect increased relative risks
of 1.14 for a BMI of X25 kgm2, 1.37 for hypertension, 1.71 for
hyperlipidemia, and 2.0 for diabetes mellitus, with 80% power,
respectively, assuming a two-sided test and a significance level of
0.05, and we were satisfied that such differences would be clinically
meaningful.
Statistical methods
ORs and 95% CIs for the association between psoriasis overall and
by psoriasis extent were calculated using conditional logistic
regression. Multiplicative interaction terms were fitted to assess the
effect modification by age and sex. Adjusted ORs were determined
by adjusting for confounders including age, sex, and duration of
follow-up time in THIN. Other possible confounders that were
explored included smoking and social class, which were measured
using Townsend scores (Phillimore et al., 1994). Further analyses
were undertaken of the association between psoriasis and disease
extent and the components of the metabolic syndrome to ensure that
the findings were not explained by individual components such as
obesity. Sensitivity analyses were undertaken using the revised NCEP
ATP III definition (glucose cut point 45.6mmol l1) and the
International Diabetes Federation definitions of metabolic syndrome
(Zimmet et al., 2005). Sensitivity analyses were also carried out using
only the first and most recent laboratory value for each individual
and in patients who did not receive psoriasis treatments that may
affect blood pressure and lipid levels (i.e., ciclosporin or acitretin).
All analyses were carried out in Stata SE10 (Stata Corporation,
College Station, TX).
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